Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 Aug 10;33(23):2492-9.
doi: 10.1200/JCO.2014.59.2782. Epub 2015 Jun 22.

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study

Owen A O'Connor  1 , Steven Horwitz  2 , Tamás Masszi  2 , Achiel Van Hoof  2 , Peter Brown  2 , Jeannette Doorduijn  2 , Georg Hess  2 , Wojciech Jurczak  2 , Poul Knoblauch  2 , Shanta Chawla  2 , Gajanan Bhat  2 , Mi Rim Choi  2 , Jan Walewski  2 , Kerry Savage  2 , Francine Foss  2 , Lee F Allen  2 , Andrei Shustov  2
Affiliations
Clinical Trial

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study

Owen A O'Connor et al. J Clin Oncol. .

Abstract

Purpose: Peripheral T-cell lymphomas (PTCLs) represent a diverse group of non-Hodgkin lymphomas with a poor prognosis and no accepted standard of care for patients with relapsed or refractory disease. This study evaluated the efficacy and tolerability of belinostat, a novel histone deacetylase inhibitor, as a single agent in relapsed or refractory PTCL.

Patients and methods: Patients with confirmed PTCL who experienced progression after ≥ one prior therapy received belinostat 1,000 mg/m(2) as daily 30-minute infusions on days 1 to 5 every 21 days. Central assessment of response used International Working Group criteria. Primary end point was overall response rate. Secondary end points included duration of response (DoR) and progression-free and overall survival.

Results: A total of 129 patients were enrolled, with a median of two prior systemic therapies. Overall response rate in the 120 evaluable patients was 25.8% (31 of 120), including 13 complete (10.8%) and 18 partial responses (15%). Median DoR by International Working Group criteria was 13.6 months, with the longest ongoing patient at ≥ 36 months. Median progression-free and overall survival were 1.6 and 7.9 months, respectively. Twelve of the enrolled patients underwent stem-cell transplantation after belinostat monotherapy. The most common grade 3 to 4 adverse events were anemia (10.8%), thrombocytopenia (7%), dyspnea (6.2%), and neutropenia (6.2%).

Conclusion: Monotherapy with belinostat produced complete and durable responses with manageable toxicity in patients with relapsed or refractory PTCL across the major subtypes, irrespective of number or type of prior therapies. These results have led to US Food and Drug Administration approval of belinostat for this indication.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest are found in the article online at www.jco.org. Author contributions are found at the end of this article.

Figures

Fig 1.
Fig 1.
Kaplan-Meier estimates. (A) Duration of response (DoR), (B) progression-free survival, and (C) overall survival by International Working Group (IWG) criteria per independent review committee assessment.
Fig 2.
Fig 2.
Maximum change from baseline sum of products of greatest diameters.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood. 1997;89:3909–3918. - PubMed
    1. Savage KJ. Peripheral T-cell lymphomas. Blood Rev. 2007;21:201–216. - PubMed
    1. O'Leary HM, Savage KJ. Novel therapies in peripheral T-cell lymphomas. Curr Oncol Rep. 2008;10:404–411. - PubMed
    1. Armitage JO. The aggressive peripheral T-cell lymphomas: 2013. Am J Hematol. 2013;88:910–918. - PubMed
    1. Chen AI, Advani RH. Beyond the guidelines in the treatment of peripheral T-cell lymphoma: New drug development. J Natl Compr Canc Netw. 2008;6:428–435. - PubMed

Publication types

MeSH terms